M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Cancer Patients Diagnosed With Unsuspected Venous Thromboembolism (VTE) on Routine Computed Tomography (CT) Scans

Conditions: Venous Thromboembolism
Cancer

Interventions: Behavioral: Questionnaires

First Posted Date: 2009-06-22

Last Posted Date: 2019-08-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1187

Registration Number: NCT00925808

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Pilot Study of Bevacizumab for Neoplastic Meningitis

Phase 1

Completed

Conditions: Neoplastic Meningitis

Interventions: Drug: Bevacizumab

First Posted Date: 2009-06-19

Last Posted Date: 2020-12-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00924820

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Obatoclax for Systemic Mastocytosis

Phase 2

Terminated

Conditions: Leukemia
Systemic Mastocytosis

Interventions: Drug: Obatoclax Mesylate

First Posted Date: 2009-06-11

Last Posted Date: 2011-11-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00918931

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Follow-up After Metastasectomy in Patients With Kidney Cancer

Active, not recruiting

Conditions: Renal Cell Carcinoma

Interventions: Other: Follow-Up Care
Other: Laboratory Biomarker Analysis

First Posted Date: 2009-06-11

Last Posted Date: 2024-03-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 86

Registration Number: NCT00918775

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Xeloda (Capecitabine) and External Beam Radiation

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Radiation: Radiation Therapy
Drug: Capecitabine

First Posted Date: 2009-06-09

Last Posted Date: 2018-07-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 33

Registration Number: NCT00916578

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence

Phase 2

Completed

Conditions: Non-Small-Cell Lung Carcinoma

Interventions: Radiation: Proton Therapy
Radiation: Photon Therapy
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2009-06-05

Last Posted Date: 2020-05-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 275

Registration Number: NCT00915005

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Sunitinib Malate in Refractory Germ Cell Tumors

Phase 2

Terminated

Conditions: Genitourinary Disease

Interventions: Drug: Sunitinib Malate

First Posted Date: 2009-06-03

Last Posted Date: 2016-04-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00912912

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Patient-Reported Outcomes Version of Common Terminology Criteria (CTCPRO) Cognitive Debriefing

Completed

Conditions: Advanced Cancers
Hematologic Diseases
Solid Tumors

Interventions: Behavioral: Interview

First Posted Date: 2009-05-27

Last Posted Date: 2014-07-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00909207

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 1 locations

Self Reported Deviations From Opioid Analgesic Prescription

Completed

Conditions: Advanced Cancers

Interventions: Behavioral: Personal Interview
Behavioral: Questionnaire

First Posted Date: 2009-05-22

Last Posted Date: 2013-06-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 201

Registration Number: NCT00907192

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis

Phase 3

Completed

Conditions: Leukemia
Fungal Infection

Interventions: Drug: Voriconazole

First Posted Date: 2009-05-20

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT00904995

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy